Anna S. Rapisarda

Valencia, VC 46010, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Ontogeny of drug-induced fatty liver disease (DIFLD): from key initiating events to disease phenotypes.

Ontogeny of drug-induced fatty liver disease (DIFLD): from key initiating events to disease phenotypes.

Journal: Archives of toxicology

Published: June 20, 2025

Unravelling drug-induced hepatic steatosis: Clinical sub-phenotypes, outcome prediction, and identification of high-concern drugs and hazardous chemical attributes.

Unravelling drug-induced hepatic steatosis: Clinical sub-phenotypes, outcome prediction, and identification of high-concern drugs and hazardous chemical attributes.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: May 09, 2025

Corrigendum to "Novel clinical phenotypes, drug categorization, and outcome prediction in drug-induced cholestasis: Analysis of a database of 432 patients developed by literature review and machine learning support" [Biomed. Pharmacother. 174 (2024) 116530].

Corrigendum to "Novel clinical phenotypes, drug categorization, and outcome prediction in drug-induced cholestasis: Analysis of a database of 432 patients developed by literature review and machine learning support" [Biomed. Pharmacother. 174 (2024) 116530].

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: May 24, 2024

Drug-Induced Fatty Liver Disease (DIFLD): A Comprehensive Analysis of Clinical, Biochemical, and Histopathological Data for Mechanisms Identification and Consistency with Current Adverse Outcome Pathways.

Drug-Induced Fatty Liver Disease (DIFLD): A Comprehensive Analysis of Clinical, Biochemical, and Histopathological Data for Mechanisms Identification and Consistency with Current Adverse Outcome Pathways.

Journal: International journal of molecular sciences

Published: March 25, 2024

A quantitative weight-of-evidence method for confidence assessment of adverse outcome pathway networks: A case study on chemical-induced liver steatosis.

A quantitative weight-of-evidence method for confidence assessment of adverse outcome pathway networks: A case study on chemical-induced liver steatosis.

Journal: Toxicology

Published: January 31, 2024

Novel clinical phenotypes, drug categorization, and outcome prediction in drug-induced cholestasis: Analysis of a database of 432 patients developed by literature review and machine learning support.

Novel clinical phenotypes, drug categorization, and outcome prediction in drug-induced cholestasis: Analysis of a database of 432 patients developed by literature review and machine learning support.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: January 25, 2024

Defined D-hexapeptides bind CUG repeats and rescue phenotypes of myotonic dystrophy myotubes in a Drosophila model of the disease.

Defined D-hexapeptides bind CUG repeats and rescue phenotypes of myotonic dystrophy myotubes in a Drosophila model of the disease.

Journal: Scientific reports

Published: December 09, 2020

Myotonic dystrophy: candidate small molecule therapeutics.

Myotonic dystrophy: candidate small molecule therapeutics.

Journal: Drug discovery today

Published: March 21, 2017

Showing 1-8 of 8

Last Updated: 09/26/2026